HCATOverviewFundamentalsDividendsTechnicalsRiskCatalystsNewsFinancial DataAIQ Pro
Current stock page

Catalysts

HCAT Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareMedical - Healthcare Information ServicesScore data as of Sep 4, 2026

HCAT

Catalysts
Health Catalyst, Inc.
Healthcare· Medical - Healthcare Information Services
AIQ Score
NeutralAIQ Edge 3/10
Low Priority
Relative Laggard
Score data as of Sep 4, 2026
Last price
$1.69
-$0.02 (-1.17%)
Latest market quote
Momentum41
Value73
Quality26
Risk Resilience39
Sentiment—
View financial data

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Nov 9, 2026

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 46/100

Momentum 41/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Sep 6, 2026 · Sentiment 19.03%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 41/100AIQ Edge 3/10 Relative Laggard
Beat rate
50%
4 of 8 reported periods
Average surprise
+10.3%
Across covered historical reports
Latest result
+33.9%
Aug 6, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Aug 6, 2026—$0.03$0.04+33.9%$69.09M$70.49M
May 11, 2026—$0.01$0.02+100.0%$69.24M$70.76M
Mar 12, 2026—$0.09$0.08-11.1%$73.97M$74.68M
Nov 10, 2025—$0.05$0.06+20.0%$74.08M$76.32M
Aug 7, 2025—$0.03$0.04+33.3%$85.14M$80.72M
May 7, 2025—$0.01$0.01+0.0%$79.16M$79.41M
Feb 26, 2025—$0.11$0.04-63.6%$79.59M$79.61M
Nov 6, 2024—$0.10$0.07-30.0%$80.68M$76.35M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Hold
1
Buy
5
Hold
12-month analyst target
$2.22
+31.36% versus current price
Based on 4 analyst observations. Targets are estimates, not predictions.
Low target
$1.75
+3.55% vs latest price
Average target
$2.22
+31.36% vs latest price
High target
$3.00
+77.51% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateNov 9, 2026

Next known earnings or reporting date.

EPS estimate-$0.02

Current analyst expectation for the upcoming report.

Revenue estimate$55.44M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score41

Where event reaction would show up first.

AIQ score46/100

Composite decision read before event confirmation.

Analyst context

Consensus
Hold
Analysts
4
Average target
$2.22
Target upside
31.36%
Target range
$1.75 - $3.00
90-day revisions
-82

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
2
Neutral
3
Negative
0
manilatimes.net · Aug 31, 2026

Health Catalyst to Participate in Upcoming Investor Conference

SALT LAKE CITY, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ('Health Catalyst', Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that members of senior management will participate in the 2026 Wells Fargo Healthcare Conference, taking place in Boston, on Wednesday, September 9, 2026 and Thursday, September 10, 2026.

finance.yahoo.com · Aug 7, 2026

Health Catalyst Q2 Earnings Call Highlights

Health Catalyst (NASDAQ:HCAT) reported second-quarter 2026 revenue above the high end of its guidance range and adjusted EBITDA at the high end of its outlook, while outlining a strategic shift following the July 31 divestiture of its Vitalware and Med-Metrix businesses. Chief Executive Officer Ben

seekingalpha.com · Aug 7, 2026

Health Catalyst anticipates $246M-$249M 2026 revenue following Vitalware divestiture (NASDAQ:HCAT)

Health Catalyst (HCAT) Q2 2026 earnings call: Vitalware divestiture, debt-free balance sheet, updated 2026 guidance, and migration churn risks—read now.

seekingalpha.com · Aug 7, 2026

Health Catalyst, Inc. (HCAT) Q2 2026 Earnings Call Transcript

Health Catalyst, Inc. (HCAT) Q2 2026 Earnings Call August 6, 2026 5:00 PM EDTCompany ParticipantsStephanie St.

manilatimes.net · Jul 28, 2026

Health Catalyst to Announce Second Quarter 2026 Operating Results and Host Conference Call on Thursday, August 6, 2026

SALT LAKE CITY, July 28, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ('Health Catalyst”, Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, will release its second quarter 2026 operating results on Thursday, August 6, 2026, after market close. In conjunction, the company will host a conference call to review the results at 5:00 pm ET on the same day.

Open full news and sentiment

Related Links

HCAT Catalysts FAQ

What are the next catalysts for HCAT stock?

HCAT's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move HCAT stock?

Upcoming events that could move HCAT include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could HCAT's next earnings report affect the stock?

HCAT's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive HCAT stock higher?

HCAT could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt HCAT stock?

HCAT could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.